• Esperion Therapeutics Inc., of Plymouth, Mich., reported top-line results from a Phase IIa study of ETC-1002 when added to statin therapy in patients with elevated levels of low-density lipoprotein cholesterol (LDL-C), with data showing that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with 0 percent in the placebo group, when added to 10 mg of atorvastatin (p < 0.0001).